Clinical Trials Browser

Phase 1/2 × Completed × rovalpituzumab tesirine × Clear all

NCT01901653 2018-08-09

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

82 enrolled 28 charts

Small Cell Lung Carcinoma